Strides Pharma Q2FY27 Revenue Up 17% to ₹14,297m, Ex-US Markets Surpass US for First Time
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17% YoY, driven by Ex-US markets (up 31% YoY). EBITDA grew 8.4% to ₹2,509m. Operational PAT was ₹1,358m. H1FY27 revenue rose 15.1% to ₹26,951m. Mr. Biren Gabhawala appointed Independent Director.
Significant revenue growth, surpassing a key market for the first time, and strategic board appointment are material events for investors.
The company reported strong revenue growth, particularly in its Ex-US markets, and achieved a milestone EBITDA. The appointment of an experienced director also adds positively to the outlook.
Strides Pharma Science Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a strong second quarter with revenue reaching ₹14,297 million, a year-on-year increase of approximately 17%. This growth was primarily driven by its Ex-US markets, which grew by 31% year-on-year to ₹6,963 million, surpassing the US business revenue for the first time. The US business also demonstrated growth, increasing by 9% year-on-year.
EBITDA for the quarter grew by 8.4% year-on-year to ₹2,509 million, reaching this milestone despite increased input material and freight costs due to geopolitical disruptions. The company remains focused on cost optimization to mitigate these pressures. Operational Profit After Tax (PAT) stood at ₹1,358 million, with Operational Earnings Per Share (EPS) at ₹14.7. Reported PAT was ₹1,341 million.
For the half-year ended September 30, 2026, revenue grew by 15.1% year-on-year to ₹26,951 million. EBITDA increased by 6.9% to ₹4,807 million, and Operational PAT was ₹2,589 million with Operational EPS at ₹28.1. Reported PAT for the half-year was ₹2,996 million.
Net debt increased by ₹2,114 million during the first half of the fiscal year due to an elongated cash-to-cash cycle and higher inventory levels. The company expects the Net Debt to EBITDA ratio to stabilize by the end of the year. Strides also announced the appointment of Mr. Biren Gabhawala as an Independent Director to its Board, effective November 1, 2026, subject to shareholder approval. His expertise is expected to strengthen the Board's financial oversight and corporate governance capabilities.
The company hosted an earnings call on October 30, 2026, at 10:00 am IST to discuss its Q2 & H1FY27 performance with senior management.
What to do with a filing like this
Strides Pharma Science Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Strides Pharma Science Limited. Read the original for the full detail.